1. Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017: JCO2017724401.

2. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25:5506–18.

3. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36–54.

4. Xiong Y, Huang BY, Yin JY. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems. Med Oncol. 2017;34:48.

5. Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol. 2016;11:976–88.

6. Kuribayashi K, Funaguchi N, Nakano T. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma. J Cancer Res Ther. 2016;12:528–34.

7. Swift LH, Golsteyn RM. Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells. Int J Mol Sci. 2014;15:3403–31.

8. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.

9. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, et al. Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol. 2018;13:165–83.

10. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–84.

11. Woods D, Turchi JJ. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther. 2013;14:379–89.

12. Arafa HM, Abdel-Hamid MA, El-Khouly AA, Elmazar MM, Osman AM. Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology. 2006;222:103–13.

13. Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol. 2008;8:7.

14. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs. 2003;63:1565–77.

15. Drottar M, Liberman MC, Ratan RR, Roberson DW. The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs. Laryngoscope. 2006;116:292–6.

16. Hatzopoulos S, Di Stefano M, Albertin A, Martini A. Evaluation of cisplatin ototoxicity in a rat animal model. Ann NY Acad Sci. 1999;884:211–25.

17. Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, et al. Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 Trial (ET). J Clin Oncol. 2017;35:402–11.

18. Salemi LM, Maitland MER, McTavish CJ, Schild-Poulter C. Cell signalling pathway regulation by RanBPM: molecular insights and desease implications. Open Biol. 2017;7:170081.

19. Suresh B, Ramakrishna S, Baek KH. Diverse roles of the scaffolding protein RanBPM. Drug Discov Today. 2012;17:379–87.

20. Palmieri D, Scarpa M, Tessari A, Uka R, Amari F, Lee C, et al. Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells. Oncotarget. 2016;7:18371–83.

21. Yard BD, Adams DJ, Chie EK, Tamayo P, Battaglia JS, Gopal P, et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016;7:11428.

22. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14:981–8.

23. Kellar A, Egan C, Morris D. Preclinical Murine Models for Lung Cancer: Clinical Trial Applications. Biomed Res Int. 2015;2015:621324

24. Horibe S, Matsuda A, Tanahashi T, Inoue J, Kawauchi S, Mizuno S. et al. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins. Life Sci. 2015;124:31–40.

25. Sears CR, Cooney SA, Chin-Sinex H, Mendonca MS, Turchi JJ. DNA damage response (DDR) pathway engagement in cisplatinradiosensitization of non-small cell lung cancer. DNA Repair. 2016;40:35–46.

26. Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI. et al. Homologous-recombination-deficient tumours aredependent on Poltheta-mediated repair. Nature. 2015;518:258–62.

27. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137–54.

28. Eustermann S, Wu WF, Langelier MF, Yang JC, Easton LE, Riccio AA. et al. Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1. Mol Cell. 2015;60:742–54.

29. Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature. 1992;356:356–8.

30. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E. et al. Specific killing of BRCA2-deficient tumours with inhibitorsof poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.

31. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–99.

32. Atabakhsh E, Bryce DM, Lefebvre KJ, Schild-Poulter C. RanBPM has proapoptotic activities that regulate cell death pathways inresponse to DNA damage. Mol Cancer Res.2009;7:1962–72.

33. Atabakhsh E, Schild-Poulter C. RanBPM is an inhibitor of ERK signaling. PLoS ONE. 2012;7:e47803.

34. Shao S, Sun PH, Satherley LK, Gao X, Ji KE, Feng YI, et al. Reduced RanBPM expression is associated with distant metastasis in gastric cancer and chemoresistance. Anticancer Res. 2016;36:1295–303.

35. Suresh B, Ramakrishna S, Kim YS, Kim SM, Kim MS, Baek KH. Stability and function of mammalian lethal giant larvae-1 oncoprotein are regulated by the scaffolding protein RanBPM. J Biol Chem. 2010;285:35340–9.

36. Zhu LL, Wang CH, Yang HP, Shu WH. Expression of cartilage antitumor component RanBP9 in osteosarcoma. J Biol Regul Homeost Agents. 2016;30:103–10.

37. Zhao Z, Cheng S, Zabkiewicz C, Chen J, Zhang L, Ye L, et al. Reduced expression of RanBPM is associated with poorer survival from lung cancer and increased proliferation and invasion of lung cancer cells in vitro. Anticancer Res. 2017;37:4389–97.

38. Hoernes TP, Huttenhofer A, Erlacher MD. mRNA modifications: dynamic regulators of gene expression? RNA Biol. 2016;13:760–5.

39. Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016;165:535–50.

40. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227–32.

41. Ghosal G, Chen J. DNA damage tolerance: a double-edged sword guarding the genome. Transl Cancer Res. 2013;2:107–29.

42. Pawlowska E, Blasiak J. DNA repair--a double-edged sword in the genomic stability of cancer cells--the case of chronic myeloid leukemia. Int J Mol Sci. 2015;16:27535–49.

43. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nature reviews. Clin Oncol (R Coll Radiol). 2012;9:144–55.

44. Jin HO, Hong SE, Woo SH, Lee JH, Choe TB, Kim EK, et al. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Cell Death Dis. 2012;3:e319.

45. Leung AWY, Veinotte CJ, Melong N, Oh MH, Chen K, Enfield KSS, et al. In vivo validation of PAPSS1 (3’-phosphoadenosine 5’-phosphosulfate synthase 1) as a cisplatin-sensitizing therapeutic target. Clin Cancer Res. 2017;23:6555–66.

46. Bonanno L. Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2013;2:160–71.

47. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003;63:6221–8.

48. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE. 2007;2:e1129.

49. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.

50. Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9.

51. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110–20.

52. Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, et al. Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer. J Transl Med. 2017;15:199.

53. Chen MK, Hung MC. Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. Am J Cancer Res. 2016;6:827–42.